Alok Swaroop
Hematology | Oncology
676 N St Clair St Ste 850
Arkes Pavilion
Chicago, IL 60611
Arkes Pavilion
Chicago, IL 60611
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 27, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2026
Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.
Journal: Leukemia & lymphoma
Published: December 23, 2025
Spatial chromatin architecture and accessibility co-profiling of mammalian tissues.
Journal: Nature methods
Published: September 11, 2025
FLT3 as a germ line driver in AML: expanding the landscape of leukemia predisposition.
Journal: Blood neoplasia
Published: August 05, 2025
Germline predispositions to myeloid malignancies: Across the lifespan.
Journal: Seminars in hematology
Published: August 05, 2025
Chromatin hubs drive key regulatory networks in leukemia.
Journal: Molecular cell
Published: December 03, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Journal: American journal of hematology
Published: September 11, 2023
Interferon and myeloproliferative neoplasms: Evolving therapeutic approaches.
Journal: BioEssays : news and reviews in molecular, cellular and developmental biology
Published: October 18, 2022
Last Updated: 09/26/2026